




Presenting Partner  
**AstraZeneca** 

## Tuesday 22 March 2022

<b>3:00pm – 6:00pm</b>	<b>Illumina Satellite Symposium – Next Level Comprehensive Genomic Profiling with Gold-Standard HRD Insights</b> <i>Crown Promenade</i>
------------------------	--

## Wednesday 23 March 2022

<b>10.00am – 12.30pm</b>	<b>ANZGOG Board Meeting</b>	
<i>Room</i>	<b>M1</b>	
<b>11.00am – 12.30pm</b>	<b>WORKSHOP - 'PRECISION SCIENCE TO PRECISION CARE'</b>	
<i>Room</i>	<b>P1</b>	
<i>Chairs</i>	<i>Caroline Ford &amp; Sophia Frentzas</i>	
11.05am – 11.15am	<b>Welcome &amp; workshop overview</b> Caroline Ford & Sophia Frentzas	
11.15am – 11.20am	<b>Top tips for scientists looking to translate their research to a trial</b> Nikola Bowden	
11.20am – 11.25am	<b>What is pharmacology &amp; why do I need to think about it for clinical trials</b> Kellie Charles	
11.25am – 11.30am	<b>Bridging the gap between the lab &amp; the clinic. What pre-clinical evidence is needed to get a trial going?"</b> Gwo Yaw Ho	
11.30am – 11.35am	<b>Novel Clinical Trial Design in the Era of Precision Medicine</b> Sophia Frentzas	
11.30am – 11.40am	<b>Do's &amp; don'ts when engaging with pharma</b> David Brown	
11.45am – 12.10pm	<b>Panel discussion</b>	
12.10pm – 12.25pm	<b>Q &amp; A (in-person &amp; virtual audience)</b>	
12.25pm – 12.30pm	<b>Wrap up &amp; How ANZGOG can help?</b>	
<b>12.30pm - 1.30pm</b>	<b>Lunch</b>	<i>Exhibition Area</i>



1.30pm – 3.30pm	<b>PURE SCIENCE SYMPOSIUM – OVARIAN CANCER</b>	
Room	<b>P1</b>	
Chair	<i>Deborah Marsh, Caroline Ford &amp; Nikola Bowden</i>	
1.30pm – 1.50pm	<b>OCR-007 – A new biomarker test for early detection of ovarian cancer</b> Carlos Salomon	
1.50pm – 2.10pm	<b>Predicting and monitoring chemoresponse using patient derived samples of ovarian cancer</b> Peter Hoffman (V)	
2.10pm – 2.30pm	<b>Australian Program of Drug Repurposing for Treatment-Resistant Ovarian Cancer</b> Michelle Wong-Brown	
2.30pm – 2.45pm	<b>High throughput discovery of synergistic drug combinations for patients with low-grade serous ovarian cancer</b> Dane Cheasley	
2.45pm – 3.00pm	<b>The genomic landscape of resistance in HR-deficient high grade serous ovarian cancer</b> Nikki Burdett	
3.00pm – 3.15pm	<b>IFFO1 &amp; HNF1 beta are methylated in ovarian cancer ascites spheroids &amp; cell-free DNA &amp; unmethylated in buffy coat DNA from women without cancer</b> Kristina Warton	
3.15pm – 3.30pm	<b>Poster Presentations</b>	
<b>3.30pm – 4.00pm</b>	<b>Afternoon Tea Area</b>	<i>Exhibition</i>
4.00pm – 5.45pm	<b>PURE SCIENCE SYMPOSIUM – OVARIAN CANCER</b>	<b>SESSION SPONSOR</b> 
Room	<b>P1</b>	
Chair	<i>Deborah Marsh, Caroline Ford &amp; Nikola Bowden</i>	
4.00pm – 4.20pm	<b>Cervical cancer screening in indigenous populations</b> Marion Saville	
4.20pm – 4.40pm	<b>Personalised medicine for endometrial cancer in Aotearoa</b> Claire Henry (V)	
4.40pm – 5.00pm	<b>Using genetics to inform epidemiological and clinical studies of endometrial cancer</b> Tracy O'Mara	
5.00pm – 5.15pm	<b>Endometrial cancer PDX-derived organoids &amp; PDX models with FGFR2c splice isoform expression are sensitive to FGFR inhibition</b> Asmeron Sengal (V)	
5.15pm – 5.30pm	<b>Prognostic features of Mucinous Ovarian Cancer: an Ovarian Tumor Tissue Analysis consortium study</b> Nicola Meagher	



Presenting Partner  
**AstraZeneca** 

5.30pm – 5.45pm	<b>Targeting the nucleolar DNA damage response as a therapeutic strategy in high-grade serous ovarian cancer</b> Anthony Jiachen Xuan	
5.15pm – 5.45pm	<b>Sponsor &amp; Exhibitor Welcome</b>	<i>Exhibition Area</i>
6.00pm – 8.00pm	<b>Welcome Reception</b>	<i>Exhibition Area</i>

## Thursday 24 March 2022

6.45am – 7.45am	<b>WomenCan Walk</b>	
08.30am	<b>ANZGOG ASM Commences</b>	
<i>Room</i>	<b>P1</b>	
8.30 am – 8.40 am	<b>Official Welcome: ANZGOG Chair Philip Beale</b>	
8.40 am – 8.45 am	<b>Presentation from our Presenting Partner AstraZeneca</b>	
8.45am – 10.35am	<b>International Keynote Presentations</b>	
<i>Room</i>	<b>P1</b>	
<i>Chair</i>	<i>Michael Burling, Pearly Khaw, Philip Beale</i>	
8.45am – 9.15am	<b>Clinical Research: Pedestrian, Personal, Personalized &amp; Powerful</b> David Gaffney (V)	
9.15am – 9.45am	<b>Role of neoadjuvant chemotherapy &amp; CRS in advanced endometrial cancer</b> Anna Fagotti (V)	
9.45am – 10.15am	<b>Pathways beyond BRCA?</b> Ana Oaknin (V)	
10.15am – 10.35am	<b>Panel Discussion</b>	
10.35am – 11.00am	<b>Morning Tea</b>	<i>Exhibition Area</i>
11.00am – 12.20pm	<b>Uterine Cancer</b>	<b>SESSION SPONSOR</b> 
<i>Room</i>	<b>P1</b>	
<i>Chair</i>	<i>Michelle Harrison &amp; Jennifer Chard</i>	
11.00am – 11.15am	<b>What is the role of lymph node assessment in the molecularly profiled endometrial cancer?</b> Bryony Simcock (V)	
11.15am – 11.30am	<b>Is isolated disease recurrence salvageable? How is it achievable &amp; are the outcomes worthwhile?</b>	

	Ming Yin Lin
11.30am – 11:45pm	<b>Immunotherapy in the setting of metastatic endometrial cancer</b> Yoland Antill
11:45am – 12:00pm	<b>Patient support needs in advanced endometrial cancer</b> Anne Mellon
12.00pm – 12.20pm	<b>Panel Discussion</b>
<b>12.20pm – 1.15pm</b>	<b>Lunch</b> <i>Exhibition Area</i>
<b>1.15pm – 1.35pm</b>	ANZGOG TRIALS -BREAKING NEWS (IGNITE INTERIM RESULTS IN CONSIDERATION TBC) CLOSED SESSION AVAILABLE TO IN PERSON DELEGATES ONLY
<i>Room</i>	<b>P1</b>
<i>Chair</i>	<i>George Au-Yeung</i>
<b>1.35pm – 2.55pm</b>	<b>Cervix &amp; Vulvar Cancer</b>
<i>Room</i>	<b>P1</b>
<i>Chair</i>	<i>David Chang &amp; Yeh Chen Lee</i>
1.35pm – 1.55pm	<b>Metastatic cervical cancer- Where to from here?</b> Linda Mileshkin
1.55pm – 2.15pm	<b>Striving for better outcomes in vulval cancer</b> Lois Eva (V)
2.15pm – 2.35pm	<b>Radiation oncologist: vulva cancer</b> David Gaffney (V)
2.35pm – 2.45pm	<b>Adjuvant chemotherapy following chemo-radiation as primary treatment for locally-advanced cervical cancer compared to chemo-radiation alone: The randomised phase 3 OUTBACK Trial (ANZGOG 0902, RTOG1174, NRG0274)</b> Linda Mileshkin
2.45pm – 2.55pm	<b>Panel Discussion</b>
<b>2.55pm – 3.55pm</b>	<b>Pathology &amp; TR-ANZGOG</b>
<i>Room</i>	<b>P1</b>
<i>Chair</i>	<i>Michelle Harrison</i>
2.55pm – 3.05pm	<b>WomenCan: Fundraising to support Initiatives</b> Karen Livingstone AM
3.05pm – 3.20pm	<b>EDEN Project Update</b> Linda Mileshkin
3.20pm – 3.35pm	<b>Tr-ANZGOG Update</b> Anna DeFazio & Claire Davies


3.35pm – 3.50pm	<b>OASIS Initiative Trial Update</b> Clare Scott & John Andrews
3.50pm – 3.55pm	<b>Questions for Initiative Leads</b>
3.55pm – 4.25pm	<b>Afternoon Tea</b> <span style="float: right;"><i>Exhibition Area</i></span>
4.25pm – 5.45pm	<b>Ovarian Cancer</b> <span style="float: right;"><b>SESSION SPONSOR</b> </span>
<i>Room</i>	<b>P1</b>
<i>Chair</i>	<i>Yoland Antill &amp; Yeh Chen Lee</i>
4.25pm – 4.45pm	<b>Exploring maintenance therapy?</b> Tarek Meniawy (V)
4.45pm – 5.05pm	<b>How to best use laparoscopy in Ovarian cancer management</b> Anna Fagotti (V)
5.05pm – 5.25pm	<b>Exploring the ovarian panel &amp; polygenic risk</b> Paul James
5.25pm – 5.35pm	<b>Abstract: Cancer susceptibility genes in non-high-grade serous ovarian cancer</b> Marina Pavanello
5.35pm – 5.45pm	<b>Panel Discussion</b>
5.45pm - 6.30pm	<b>Posters &amp; Drinks</b> <span style="float: right;"><i>Exhibition Area</i></span>
<b>EVENING OPTIONS</b>	<b>FREE EVENING FOR DINNER WITH FRIENDS &amp; COLLEAGUES</b>

<b>Friday 25 March 2022</b>	
7.30am-8.30am	<b>AstraZeneca Education Breakfast</b> Invitation Only <span style="float: right;"></span>
<i>Room</i>	<b>M3 &amp; M4</b>
<i>Chair</i>	
8.30am – 10.15am	<b>Quality &amp; Survivorship</b>
<i>Room</i>	<b>P1</b>
<i>Chair</i>	<i>Catherine Adams, Wanda Lawson &amp; Anne Mellon</i>
8.30am – 8.40am	<b>Abstract: Exploring women’s experiences of post-treatment care with high-intermediate &amp; high-risk endometrial cancer: A qualitative study</b> Nicole Kinnane (V)
8.40am – 8.50am	<b>Abstract: Ovarian cancer: investigating Variation in care &amp; survival, Aetiology &amp; Risk factors to Improve outcomes in Australia via National data linkage. The OVARIAN study</b> Penelope Webb (V)


8.50am – 9.05am	<b>"Māku &amp; e hanga tōku nei whare" A discussion of survivorship within a Māori viewpoint</b> Sarah Te Whaiti (V)
9.05am – 9.15am	<b>Question &amp; Answer</b>
9.15am – 10.25am	<b>Panel Discussion: Ovarian Cancer - Why cease treatment, How should we decide &amp; Who should make the decision?</b> Ken Lambert, Janine Lombard (V), Geoff Otton (V), Wanda Lawson, Anne Mellon, Catherine Adams
<b>10.25am – 10.55am</b>	<b>Morning Tea</b> <span style="float: right;"><i>Exhibition Area</i></span>
<b>10.55am – 11.05am</b>	<b>Consumer Group Presentation – ‘CRP &amp; Consumer Pathways to Precision Care’</b>
<i>Room</i>	<b>P1</b>
<i>Chair</i>	<i>Wanda Lawson</i>
<b>11.05am – 1.00pm</b>	<b>Trial Concepts &amp; Updates</b>
<i>Room</i>	<b>P1</b>
<i>Chair</i>	<i>Alison Davis (RAC Chair) &amp; Philip Beale (ANZGOG Chair)</i>
11.05am – 11.25am	<b>Concept A randomized Phase 2 clinical trial comparing bevacizumab vs niraparib as maintenance therapy in surgical high risk patients with homologous recombinant proficient high grade cancer of ovary, fallopian tubes &amp; peritoneum</b> Chee Lee (V)
11.25am – 11.30am	<b>Concept Question &amp; Answer</b>
11.30am – 11.40am	<b>Trials in Start-Up   Developing Your Trial with ANZGOG</b> Alison Davis & John Andrews
11.40am – 11.55am	<b>Extending the value of quality of life measurement in cancer: Enhanced Services offered by CQUEST</b> Brendan Mulhern
<b>11.55am – 1.00pm</b>	<b>Trial Updates</b>
<i>Room</i>	<b>P1</b>
<i>Chair</i>	<i>John Andrews &amp; Clare Scott</i>
11.55am – 12.10pm	<b><u>Ovarian Cancer Trials</u></b> <ul style="list-style-type: none"> <li>• SOLACE2 - Clare Scott (V)</li> <li>• ECHO - Sandi Hayes (V)</li> <li>• IGNITE - George Au-Yeung (V)</li> </ul>
12.10pm – 12.15pm	<b>Question &amp; Answer</b>
12.15pm – 12.30pm	<b><u>Collaborative Trials</u></b> <ul style="list-style-type: none"> <li>• ICON9 - Linda Mileshekin (V)</li> <li>• STICS - Kelly-Anne Phillips (V)</li> <li>• EMBRACE - Katrin Sjoquist (V)</li> </ul>
12.35pm – 12.40pm	<b>Question &amp; Answer</b>

12.40pm – 12.55pm	<b>Surgical Trials</b>			
	<ul style="list-style-type: none"> <li>HyNOVA - Rhonda Farrell (V)</li> <li>ENDO3 - Andreas Obermair (V)</li> </ul>			
12.55pm – 1.00pm	<b>Question &amp; Answer</b>			
1.00pm - 2.00pm	<b>Lunch</b> <i>Exhibition Area</i>		<b>3 x Pipeline Presentations</b> Presented by AstraZeneca, GSK, Alkermes <i>Room: M4</i>	
2.00pm – 3.30pm	<b>Specialised Workshops</b>			
<b>W1:</b> Radiation Oncology Workshop	<b>W2:</b> Gynae Nurses Workshop Workshop Sponsor – Eisai	<b>W3:</b> Consumer Education Workshop	<b>W4:</b> Study Coordinators Workshop	<b>W5</b> Rare Cancers Workshop
<i>Jennifer Chard, David Chang, Pearly Khaw</i>	<i>Anne Mellon</i>	<i>Wanda Lawson</i>	<i>Donna Long</i>	<i>Yeh Chen Lee, Michael Burling &amp; Lawrence Kashermann</i>
<i>Room: M3</i>	<i>Room: M2</i>	<i>Room: M2</i>	<i>Room: M4</i>	<i>Room: P1</i>
2.00pm – 2.30pm <b>Vulva contouring</b> – David Gaffney Q&A with David Gaffney	2.00pm - 2.30pm <b>Indigenous Cervical Screening</b> Ashlee Williams  <i>This presentation is a joint presentation for the Gynae Nurses Workshops &amp; Consumer Education Workshop in M2</i>		2:00pm – 2:20pm <b>Satellite Site perspective</b> Narelle McPhee	2:05pm – 2:20pm <b>Pathways for Rare Gyne Tumours: Diagnosis, Treatment, Consensus</b> Clare Scott
2.30pm – 3.30pm <b>Dose/fractionation, volumes to include?</b> -Real life case discussions	<i>Room: M2</i>	<i>Room: M1</i>	2:20pm – 2:40pm <b>Primary Site perspective</b> Kylie Shackleton	2:20pm – 2:35pm <b>Molecular profiling in 100 rare gynae cancers</b> Holly Barker
4.00pm – 5.30pm <b>GROC Meeting</b>	2.30pm – 3.00pm <b>Entwine Study: Screening for Distress in Women with Gynaecological Cancer</b> Charlotte Seib	2.30pm - 3.00pm <b>Tele-Health at Royal Hobart Hospital</b> Allison Black	2:40pm – 3:00pm <b>TARGET TP pilot success</b> A/Prof Kate Burbury	2:35pm – 2:50pm <b>Rare Gyne Tumours in the MOST program: where are we at?</b> Damien Kee
	3.00pm – 3.30pm <b>TRACEBACK – Responses to Involvement</b> Rachel Delahunty	3.00pm - 3.30pm <b>Tele-Health within the Albury Wodonga Regional Cancer Centre</b> Craig Underhill (V)	3:00pm – 3:30pm <b>Interactive panel discussion and Q&amp;A</b>	2:50pm – 3:05pm <b>Histopathology for Rare Gyne Tumours</b> Lyndal Anderson (V)
				3:05pm – 3:20pm <b>Rare Gyne Tumours &amp; Trials: how can we improve outcome</b> Chee Lee (V)



3.30pm – 4.00pm	Afternoon Tea <span style="float: right;">Exhibition Area</span>		
4.00pm – 5.30pm	Specialised Workshops (continued)		
<b>W1: Radiation Oncology Workshop</b> <i>Continued</i>	<b>W2 – W4</b> Wellness & Resilience	<b>W5</b> Rare Cancers Workshop <i>Continued</i>	
Room: <b>M3</b>	Room: <b>M2</b>	Room: <b>P1</b>	
	Cath Adams  <i>Combined with Gynae Nurses, Consumer Education &amp; Study Coordinators Workshops</i>	4:05pm – 4:45pm <b>Panel Discussion: Low grade serous ovarian cancer</b> Michael Burling Anna DeFazio Bo Gao (V)  4:45pm – 5:25pm <b>Panel Discussion: Leiomyosarcoma</b> Lawrence Kasherman Clare Scott Inger Olesen (V) Genevieve Dall Orla McNally Pearly Khaw	
7.00pm-11.00pm	CONFERENCE DINNER Zinc at Federation Square Delegates to make their own way to venue		Dinner Sponsor 

## Saturday 26 March 2022

7.30am - 8.30am	RAC 2 Breakfast meeting	
Room	<b>M3</b>	
8.45am -10.30am	Controversies In Gynaecological Cancer	Session Sponsor 
Room	<b>P1</b>	
Chair	Michael Burling & Pearly Khaw	



8.45am - 9.10am	<b>Is it unethical to treat patients with endometrial cancer NOT knowing their molecular profile?</b> Kate Webber	
9.10am – 9.35am	<b>HPV – More important than ever in gynae cancers?</b> Alison Brand	
9.35am – 9.50am	Panel Discussion	9.45am – 10.30am
9.50am – 10.00am	<b>Abstract: Ipilimumab &amp; nivolumab combination immunotherapy in patients with rare gynaecological malignancies: results of a multi-centre, phase 2 trial (CA209-538)</b> Oliver Klein	<b>The Role of the Consumer in Research</b> <i>Room: M3</i> Chair: Wanda Lawson  Leonie Young, Peer Support Coordinator – Choices
10.00am – 10.10am	<b>Abstract: “Chemo – but it sucks”: A survey of Australian &amp; New Zealand oncologists on the treatment of mucinous ovarian cancer</b> Kylie Gorringer	
10.10am -10.20am	<b>Abstract: Expecting the unexpected: Identification of actionable genetic variants using multigene panel testing in uterine cancer patients</b> Anchit Khanna (V)	
10.20am – 10.30am	Panel Discussion	
10.30am – 10.50am	<b>Morning Tea</b> <span style="float: right;"><i>Exhibition Area</i></span>	
10.50am - 11.20am	<b>ANZGOG INFORMATION</b>	
<i>Room</i>	<b>P1</b>	
<i>Chair</i>	<i>Philip Beale</i>	
10.50am -11.05am	<b>ANZGOG Survivors Teaching Students Program</b> Helen Gooden	
11.05am -11.20am	<b>ANZGOG Chair Update</b> Philip Beale	
11.20am – 12.30pm	<b>TUMOUR BOARD</b> <i>PANEL: JULIE LAMONT, DAVID CHANG, SUMI ANANDA, MARSALI NEWMAN, GEORGE AU-YEUNG</i>	
<i>Room</i>	<b>P1</b>	
<i>Chair</i>	<i>Michelle Harrison</i>	
11.20am –11.40am	<b>Case 1: Ovary</b> Michelle Harrison	
11.40am -12:00pm	<b>Case 2: Endometrial</b> Yoland Antill	
12:00pm - 12.20pm	<b>Case 3: Cervix</b> Michelle Harrison	



Presenting Partner



12.20pm – 12.30pm	<b>Panel Discussion</b>
12.30pm – 12.35pm	<b>Thank you to delegates</b>
12.35pm	<b>Meeting Concludes</b>